The Supreme Court is set to hear arguments in a patent case that could change the way generic drug companies market and label copycat products. The case involves Amarin Pharma alleging that its patents were infringed when generic drugmaker Hikma Pharmaceuticals made a copycat version of a heart drug derived from fish oil and promoted it through press releases and marketing materials for a use still protected by patents. The court will decide if a drug labeled only for non-patented uses can infringe on patents if the manufacturer induces doctors to prescribe it. This could clarify how far generics can go in marketing their products and establish what evidence a brand-name drugmaker needs to prove that a generic company actively encouraged doctors to adopt a drug.